Why do teams with genuinely innovative technology often approach investors without a commercially-minded regulatory pathway? I’ve noticed this pattern with some of the deep tech, medtech and climate tech founders I advise, where regulatory work is seen as something distinct from building a company. I also see the results: stalled fundraising, or, if rushed, closing rounds on worse terms than they should have accepted. Founders may even have lawyers or university support, but still lack the strategic mindset to use regulation as a pre-fundraising de-risking tool.
My message: map the regulatory pathway before you open the fundraising round, not after.
The sequencing argument, redux
Regular readers of the Brief will recognize this argument building across recent issues:
- Structure before capital. The 63-Year Clause showed what happens when founders sign term sheets without leverage.
- Pilot before equity terms. Build the corporate relationship before the investor conversation.
- IP narrative before diligence. Map the four IP layers before the first investor meeting.
- Regulatory pathway before the round opens; the subject of this post.
Founders who raise fastest and get the best terms are those who have de-risked the right things, in the right order, before going to market. For research-based startups, investors are laser-focused on de-risking and commercial viability, rather than pure technological innovation. According to recent data, 70% of biotech Series B rounds now include detailed regulatory risk mitigation plans specifically because investors require them (HTD Health MedTech Investment Trends 2026). And for this to happen, risk mitigation often starts at inception.
Two cases illustrate this: one in medtech, one in Europe’s energy sector.
Case 1: Medtech regulatory landscape
I’m currently working with an advanced medical device venture: US-based, with proprietary technology and strong clinical validation. Rather than opening a SAFE round with a pitch deck, we structured a manufacturing LOI first, and initiated the regulatory sequencing. Right now the company has NIH and NSF applications under review in parallel. In this case, the regulatory pathway is being mapped and de-risked before the initial investor discussions. It acts as catalyst to funding, not the other way around..
This is important because Medtech investors in 2026 are writing bigger checks to fewer, better-prepared companies, such as those have cleared regulatory barriers or have demonstrated a credible path to clearance. Deal sizes are rising while counts are falling: in the first half of 2025, $8.2 billion was invested across 421 deals, on pace for $16.4 billion annually, the second-highest total since 2021. Generalist VCs, who often lack the expertise to assess regulatory risk themselves, are increasingly prioritizing companies that have already done the work.
There are three FDA pathways every medtech founder needs to understand:
510(k) (3–12 months) is the most common route. It demonstrates that a device is substantially equivalent to an existing legally marketed device, known as a predicate. The predicate selection is the most consequential early decision, and getting it wrong can add delays and significant cost.
De Novo (12–24 months) applies to genuinely novel technologies without a close equivalent on the market. This is more rigorous than 510(k) but creates a new regulatory category that can benefit the company long term. Think of two companies with similar technologies: one discovered their De Novo requirement early, adjusted their claims strategy, and saved an estimated twelve months of runway. The other discovered it in late-stage development.
PMA (2–5 years) is the most demanding pathway, reserved for the highest-risk devices. This requires full clinical trial data and scientific review. Not the right pathway to stumble into without knowing it was coming.
Still unclear? Before you commit to any of these three pathways, there is one free tool that very few PhD founders use: the Q-Sub, or pre-submission meeting. The Q-Sub provides direct FDA feedback on predicate strategy and device classification before you need to commit to a full submission. Moreover, founders who have completed a Q-Sub walk into investor diligence with documented FDA engagement, which itself is a specific, verifiable de-risking signal that most early-stage device founders lack.
A note on where to start. Most of what this section describes requires expertise that sits outside the lab or classroom. A PhD founder who has spent five years developing a novel medical technology knows the science in extraordinary depth, but almost never has navigated a regulatory submission, selected a predicate device, or mapped a reimbursement pathway. That is not a gap to be embarrassed about; it is a structural reality. Academic training doesn’t cover this, and most TTOs focus on IP transfer rather than regulatory strategy. But the gap between the two is where most medtech PhD founders are challenged. If you have access to a regulatory consultant, a medtech accelerator, or a commercialization advisor, they can help map this pathway. As a founder, you don’t need to become a regulatory expert.
On timing: The current administration’s changes to FDA leadership and staffing have introduced uncertainty around review timelines and guidance updates. The instinct is to wait for more clarity, but that is wrong. Forward-thinking regulatory teams are treating current constraints as a signal to act early. In fact, well-prepared submissions can capitalize on competitor hesitancy and avoid future backlogs. For companies looking to a Series A, investors expect an identified reimbursement pathway along with a regulatory one. Investors expect both, and being unclear about either can lower valuation and limit your ability to raise capital for growth.
Case 2: EU’s deep tech energy regulatory landscape
The regulatory landscape for European deep tech founders looks entirely different than US medtech, but the sequencing principle is identical.
I’m currently working with a deep tech energy venture in Europe: Swiss-based, US entity, with a dual commercial model that combines IP licensing with energy market sales. The pathway here is EU energy market regulations, grid interconnection requirements, and potential hardware certification for European deployment. In this case, the regulatory complexity is not a near-term obstacle. But mapping it now, before the IP is commercialized, can prevent structural decisions that would need to be rebuilt later at significant cost. That mapping is happening now, before the first commercial deployment, not after.
For European deep tech founders, the EIC funding stack is itself a regulatory de-risking sequence, with each stage generating the validation data that makes the next investor conversation easier.
The EIC Board published a statement this month: Europe’s next challenge is not the lack of innovation. It is getting promising technologies from breakthrough research to industrial deployment and market adoption. Europe’s challenges include fragmented regulation, long permitting timelines, and limited access to sustained funding across development stages, compared to the US. This is the structural problem, and the EIC pathway is one response to it.
Specifically:
EIC Pathfinder: early-stage breakthrough research, grants up to €3M.
EIC Transition: bridge from research to commercial application, grants up to €2.5M. This application process itself forces the commercialization mapping that founders need, and is important for that reason alone.
EIC Accelerator: this has a scale-up function, with a €634M budget in 2026, offering grants below €2.5M plus equity to €10M. Open for dual-use applications since June 2026.
STEP Scale Up: a €300M pool available for for late-stage deep tech, with investment size from €10M–€30M.
If there is any interest in benefiting from this EU funding and support stack, there three EU regulatory developments (in the energy sector for this example) worth considering:
- The EU’s day-ahead electricity market moved to 15-minute trading intervals in September 2025. For a deep tech energy venture with an energy arbitrage model, this creates more commercial opportunities, but only if the technology is mapped to the new market structure before commercialization begins.
- The EU Data Centre Energy Efficiency Package targets carbon-neutral data centers by 2030. For energy delivery technologies targeting data center infrastructure, compliance it is a critical market entry credential.
- REPowerEU targets 42.5% renewable energy by 2030. Alignment creates a public procurement pathway that functions as a regulatory de-risking signal for investors, providing access to the commercial market.
The global regulatory picture
These two cases deal with specific sectors in the US and Europe, but many other key markets have their own regulatory landscape and peculiarities. Here is how a few key pathways compare:
ONE ACTION
Before your next or initial investor conversation, map your regulatory pathway.
For medtech founders: Find out which FDA pathway applies to your technology this week: 510(k), De Novo, or PMA. If you don’t know, that is the first conversation to have with a regulatory consultant, your TTO, or a medtech accelerator that provides regulatory coaching. Once you know the pathway, ask about booking a Q-Sub to provide direct FDA feedback. This is one of the most credible de-risking signals you can show an investor. Map your reimbursement pathway alongside it.
For EU deep tech energy founders: Map three regulatory touch points your technology will encounter when it enters its first commercial market. Areas such as grid interconnection requirements, EU energy efficiency certification, CE marking for hardware components, procurement compliance under REPowerEU. Use the EIC Transition application as the forcing function to commercialize your research.
For all sectors: Add a regulatory milestone timeline to your pitch materials. Include dates, costs, and what each milestone unlocks commercially. If you can’t build that slide without outside help, that is useful information about what you need to research further.
Founders who successfully closed funding rounds in deep tech and medtech didn’t wait for investors to ask regulatory questions. They answered them before the discussion started.
Sources
- Alpha Sophia: “Raising Capital in 2026 for US Medical Device Startups” (October 2025)
- HTD Health: “MedTech Investment Trends & Predictions for 2026” (January 2026)
- HTD Health: “Venture Capital Trends in MedTech” (January 2026)
- Qubit Capital: “Mastering Biotech Startup Funding Strategies” (April 2026)
- Crowley Law: “Why Medical Technology Startup Funding Is Falling in 2025” (November 2025)
- Complizen: “How to Fund a Medical Device Startup” (August 2025)
- The FDA Group: “10 Essential Tips for a Successful 510(k) Submission in 2026” (January 2026)
- Educo Life Sciences: “FDA De Novo vs 510(k) vs PMA Comparison” (April 2026)
- EIC Board Statement: “Faster Deployment of Deep Tech for Energy Resilience” (June 24, 2026)
- EIC Work Programme 2026 (November 2025)
- EIC Transition 2025 Results (February 2026)
- EU Startup and Scaleup Strategy (June 2026)
- Rasph: “EIC Selects 40 New Transition Projects” (February 2026)
- Open Access Government: “EU Innovation Body Urges Faster Rollout of Deep Tech” (June 2026)
Photo by ThisisEngineering on Unsplash